IP Library Granted Patent US 7,655,248
Granted Patent B2
US 7,655,248 · App. 10/311,837 · Granted Feb 2, 2010

Compositions and methods for treatment of candidiasis

Assignee: Hunter Immunology Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,655,248
App. No.
10/311,837
Granted
Feb 2, 2010
Kind
B2
Abstract

The present invention relates to novel oral compositions and vaccines, and in particular to oral vaccines for the prevention or therapy of candidiasis.

Claims (13)

1. A method of reducing the risk of or therapeutic treatment of a condition caused by Candida albicans colonization or infection, comprising administering to a subject requiring such treatment a therapeutically effective amount of a composition formulated for oral administration or subcutaneous injection comprising inactivated blastospores of Candida albicans.

2. The method according to claim 1 , wherein the condition is mucositis.

3. The method according to claim 1 , wherein the condition is selected from the group consisting of recurrent/persistent stomatitis, recurrent vulvovaginal candidiasis, oesophagitis and lower urinary tract or bowel colonisation.

4. The method according to claim 1 , further comprising the administration of an adjuvant before, during, or after cessation of treatment.

5. The method according to claim 4 , wherein the adjuvant is administered orally.

6. The method according to claim 4 , wherein the adjuvant is administered subcutaneously.

7. The method according to claim 1 , wherein the condition is selected from the group consisting of oral, nasopharyngeal and respiratory tract colonization.

8. The method according to claim 1 , wherein the condition is oral colonization.

9. The method according to claim 1 , further comprising administration of the probiotic before, during, or after cessation of treatment.

10. A method of reducing the risk of or therapeutic treatment of a condition caused by Candida albicans colonization or infection, comprising administering to a subject requiring such treatment a therapeutically effective amount of a composition formulated for oral administration comprising inactivated blastospores of Candida albicans and a probiotic.

11. The method of claim 9 or 10 , wherein the probiotic is a probiotic bacterium.

12. The method of claim 11 , wherein the probiotic bacterium is a lactic acid bacterium.

13. The method according to claim 12 , wherein the lactic acid bacterium is Lactobaccillus acidophilus.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2014
From: HUNTER IMMUNOLOGY PTY LTD
To: BIOXYNE LTD
Reel/Frame 032452/0296 →
CHANGE OF NAME Recorded Mar 17, 2014
From: HUNTER IMMUNOLOGY LTD
To: HUNTER IMMUNOLOGY PTY LTD
Reel/Frame 032457/0107 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2008
From: CANDIVAX PTY LTD
To: HUNTER IMMUNOLOGY LIMITED
Reel/Frame 021300/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2003
From: CLANCY, ROBERT; PANG, GERALD; SHOKROLLAH, ELAHI
To: CANDIVAX PTY LTD.
Reel/Frame 014819/0725 →
Priority Claims (2)
AU PQ 8214 · Jun 19, 2000 · national
AU PQ 8294 · Jun 22, 2000 · national
Continuity (1)
Related Publication 20040037854A1 · Feb 26, 2004